INTRODUCING IPS: A PROGNOSTIC BIOMARKER FOR PATIENTS ON ICI THERAPY /// LEARN MORE INTRODUCING IPS: A PROGNOSTIC BIOMARKER FOR PATIENTS ON ICI THERAPY /// LEARN MORE

TEMPUS STUDIES

Accelerate your clinical trials by leveraging our end to end solutions

We partner with forward-thinking life science companies to sponsor studies of their drugs, devices, and diagnostics, integrating our life science solutions to help achieve their objectives.

Our Differentiators

  • ~7M

    de-identified multimodal records

  • 90+

    sites representing 500+ clinical locations

  • CDx development

    collaborations with several life science partners

  • Industry-leading regulatory expertise

    Tempus can submit and maintain the investigational new drug application (IND) for drug development studies

image description

Collaboration Timeline

Our end to end approach has been used to accelerate clinical trial start-up and execution for the PAVO study.

Read more about a Tempus-sponsored interventional study
  • 5 months from study hypothesis to IND submission and IRB approval
  • 60 days from IRB approval to first site activated, leveraging our TIME Trial Program, a just-in-time network of providers
  • 10 days from first site activated to first patient dosed
image description

Leverage our precision medicine infrastructure to accelerate clinical development using an innovative data-driven approach from study concept to registrational filing.

CONTACT TEMPUS